Health Condition 1: null- Recurring platinum-resistant ovarian cancer
Conditions
Interventions
Intervention1: Company Serial No.: ON 01910.Na
Chemical Name: sodium salt of (E)-2,4,6-trimethoxystyryl-3-carboxymethylamino-4-
methoxybenzyl sulfone
: Dose: 2400mg biweekly for 3 weeks in 4 weeks
Sponsors
Onconova Therapeutics Inc
Max Neeman International
Eligibility
Inclusion criteria
Inclusion criteria: 1. Women with ovarian cancer aged greater than or equal to 18 yeras to les than or equal to 65 years with measurable disease who have shown recurrent disease within 6 months of the last dose of cisplatin- or carboplatin-based chemotherapy. a. Measurable disease will be defined as lesions that can be accurately measured in at least one dimension with longest diameter greater than or equal to 20 mm using conventional techniques or gretaer than or equal to 10 mm with spiral CT scan. 2. Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2 (see Attachment 1 of Protocol). 3. No more than 3 prior chemotherapy regimens. 4. Disease-free period of more than 5 years from prior malignancies other than ovarian (except curatively treated basal cell carcinoma, squamous cell carcinoma of the skin or carcinoma in situ of the cervix). 5. All patients of childbearing potential must use at least one form of contraception as approved by the Investigator prior to study and up to 30 days beyond the last administration of study drug. 6. Women of childbearing potential must have a negative serum betaHCG pregnancy test at screening. 7. Willing to adhere to the prohibitions and restrictions specified in this protocol. 8. Patient (or her legally authorized representative) must have signed an informed consent document
Exclusion criteria
Exclusion criteria: 1. Evidence of complete or partial bowel obstruction. 2. Need for IV hydration or Total Parenteral Nutrition. 3. Inability to comply with study and/or follow-up procedures. 4. Life expectancy of less than 12 weeks. 5. Prior radiotherapy to greater than one third of hematopoietic sites. 6. Uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia. 7. Active infection not adequately responding to appropriate therapy. 8. Hyponatremia (defined as serum sodium value of 134 mEq/L) 9. Total bilirubin greater than or equal to 1.5 mg/dL not related to hemolysis or Gilbert?s disease, AST/ALT or alkaline phosphatase greater than or equal to 2 X upper limit of normal (ULN). 10. Serum creatinine greater than or equal to 2.0 mg/dL. 11. ANC 1500/mm3, platelets 100,000/mm3; hemoglobin less than 9 g/dL. 12. Ascites requiring active medical management including paracentesis for more than twice a month. 13. Women patients who are pregnant or lactating or have a positive serum betaHCG pregnancy test at screening. 14. Major surgery without full recovery or major surgery within 3 weeks of ON 01910.Na treatment start. 15. Uncontrolled hypertension (defined as a systolic pressure greater than or equal to 160 and/or a diastolic pressure greater than or equal to 110). 16. New onset seizures (within 3 months prior to the first dose of ON 01910.Na) or poorly controlled seizures. 17. Brain metastases including any of the following: a. Evidence of cerebral edema by CT scan or MRI b. Evidence of disease progression on prior imaging studies c. Requirement for steroids d. Clinical symptoms of brain metastases 18. Any concurrent, and/or within 4 weeks of the first dose of study drug, investigational agent or chemotherapy, radiotherapy or immunotherapy 19. Psychiatric illness/social situations that would limit the patients ability to tolerate and/or comply with study requirements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival (PFS) rates in patients with platinum-resistant ovarian cancerTimepoint: 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Objective response rates (ORR), duration of response, duration of stable disease, clinical benefit [CR+PR+SD] and overall survival [OS]Timepoint: At 2 months, 4 months, 6 months;2.Tolerability of ON 01910.Na (where CR: Complete Response, PR: Partial Response, SD: Stable Disease) Timepoint: During the Entire study duration | — |
Countries
India
Contacts
Public ContactDr Manmohan Acharya
Onconoca Therapeutics, Inc.
Outcome results
None listed